Literature DB >> 10687857

Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor.

S M Yoh1, M L Privalsky.   

Abstract

Thyroid hormone receptors (T3Rs) both repress and activate gene transcription by interacting with auxiliary factors denoted corepressors and coactivators. Resistance to thyroid hormone (RTH) syndrome in humans is manifested as a failure to respond properly to elevated circulating thyroid hormone. RTH syndrome has been mapped to T3Rbeta mutations that alter the transcriptional properties of the receptor, resulting in a dominant negative phenotype. We report here a characterization of a series of RTH mutant T3Rs that exhibit unusual interactions with corepressor. Two mutations in receptor helix 11 (delta430, delta432) greatly enhance the ability of the mutant receptors to bind to corepressor. A distinct mutation, V264D, in an 'omega loop' region of the receptor, impairs corepressor release but does not fully eliminate the ability to recruit coactivator. These mutations reveal novel determinants that regulate the interaction of the T3R with important ancillary cofactors, and that are disrupted in a human endocrine disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10687857     DOI: 10.1016/s0303-7207(99)00201-4

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  13 in total

1.  Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression.

Authors:  Behnom Farboud; Herborg Hauksdottir; Yun Wu; Martin L Privalsky
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

2.  Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors.

Authors:  Michael L Goodson; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

3.  Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2005-01-13

4.  Lack of TSH inhibition by exogenous L-T4 in a patient with follicular thyroid carcinoma.

Authors:  R Bruno; P Giannasio; P Bellitti; R Sinisi; F Arturi; D Russo; G Costante
Journal:  J Endocrinol Invest       Date:  2005 Jul-Aug       Impact factor: 4.256

5.  Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

6.  Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2009-04-30

7.  Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4alpha1: modulation by the F domain.

Authors:  Michael D Ruse; Martin L Privalsky; Frances M Sladek
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

8.  Novel oncogenic actions of TRbeta mutants in tumorigenesis.

Authors:  Celine J Guigon; Sheue-yann Cheng
Journal:  IUBMB Life       Date:  2009-05       Impact factor: 3.885

9.  A thyroid hormone receptor mutation that dissociates thyroid hormone regulation of gene expression in vivo.

Authors:  Danielle S Machado; Amin Sabet; Leticia A Santiago; Aniket R Sidhaye; Maria I Chiamolera; Tania M Ortiga-Carvalho; Fredric E Wondisford
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

Review 10.  Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.

Authors:  Fumihiko Furuya; Changxue Lu; Celine J Guigon; Sheue-Yann Cheng
Journal:  Steroids       Date:  2008-10-30       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.